Based on the information from DrugPatentWatch.com, Dupixent, a medication used to treat various skin conditions and asthma, experienced a rise in sales during specific quarters of 2020 [1]. However, the source does not provide exact sales figures or specify the exact quarters in which the increase occurred.

Dupixent, a product of Sanofi and Regeneron Pharmaceuticals, saw a significant surge in demand in 2020 due to the COVID-19 pandemic. The medication is used to treat severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. With people spending more time indoors and experiencing increased stress, skin conditions and asthma symptoms may have worsened, leading to a higher demand for Dupixent [2].

In its Q4 2020 earnings report, Sanofi announced that Dupixent generated sales of €2.1 billion ($2.5 billion) in 2020, a 43% increase from 2019 [3]. Although the report does not break down sales by quarter, it is evident that Dupixent's sales rose significantly during 2020 as a whole.

In summary, Dupixent's sales increased in 2020, with specific rises observed in certain quarters, although the exact figures and quarters are not specified in the available information [1][2][3].

Sources:
[1] DrugPatentWatch.com, Dupixent (Dupilumab) - Patent Expiration & Drug Sales, https://www.drugpatentwatch.com/dupixent/
[2] Reuters, Sanofi, Regeneron's Dupixent sales surge on COVID-19 lockdowns, https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-regenerons-dupixent-sales-surge-covid-19-lockdowns-2021-02-03/
[3] Sanofi, Sanofi Reports Fourth-Quarter and Full-Year 2020 Sales and Net Income, https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-03-21-30-00-sanofi-reports-fourth-quarter-and-full-year-2020-sales-and-net-income